Bladder Cancer Clinical Trials in Philadelphia, Pennsylvania
10 studies are recruiting for bladder cancer in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Sidney Kimmel Comprehensive Cancer Center Thomas Jefferson University, Philadelphia, Pennsylvania
- Locations
- 20 in total
- Run by
- IDEAYA Biosciences
-
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
The goal of this study is to evaluate the safety and effectiveness of EVOLVE104 in participants with advanced urothelial and squamous cell carcinomas who have previously taken standard treatment options, have declined or have been ineligible for treatment with these medications. Participants with a…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania
- Locations
- 16 in total
- Run by
- EvolveImmune United, Inc
-
DESTINY-PANTUMOUR04
This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world…
- Stage
- Not phased
- Ages
- 18 to 130
- Site
- Research Site, Philadelphia, Pennsylvania
- Locations
- 18 in total
- Run by
- AstraZeneca
-
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
This is a global, multicenter, randomized, open-label, Phase 2/3 study of Dato-DXd plus carboplatin or cisplatin versus gemcitabine plus carboplatin or cisplatin in participants with la/mUC who progressed during or after EV plus pembrolizumab combination treatment. This trial will start with part A…
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- Research Site, Philadelphia, Pennsylvania
- Locations
- 100 in total
- Run by
- Daiichi Sankyo
-
Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer
The primary objective of this Phase I study is to establish the safety of adjuvant concurrent immunotherapy and radiation therapy for urothelial bladder cancer.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- University of Pennsylvania, Philadelphia, Pennsylvania
- Run by
- Abramson Cancer Center at Penn Medicine
-
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
The proposed project will have two separate cohorts. The first will be to perform a more in-depth qualitative assessment of the barriers and facilitators for treatment compliance for non-muscle invasive bladder cancer. The second arm will be to create and test a BCG at home program. Participants in…
- Stage
- Not phased
- Ages
- 18 and older
- Site
- Abramson Cancer Center, Philadelphia, Pennsylvania
- Run by
- Abramson Cancer Center at Penn Medicine
-
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: * Does CP-383 slow or stop the growth of cancer in patients with advanced cancer * What medical prob…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- University of Pennsylvania, Philadelphia, Pennsylvania
- Locations
- 13 in total
- Run by
- Tasca Therapeutics
-
Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy
Subjects will be randomized into 2 groups (stent or no stent) prior to radical cystectomy with ileal conduit urinary diversion (RCIC). They will follow the standard of care and be enrolled in the study for 12 months post-op. Risk of post-op complications will be analyzed.
- Stage
- Not phased
- Ages
- 18 to 85
- Site
- Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
- Locations
- 2 in total
- Run by
- Thomas Jefferson University
-
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania
- Locations
- 21 in total
- Run by
- Clasp Therapeutics, Inc.
-
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…
- Stage
- Not phased
- Ages
- Any age
- Site
- Massive Bio SYNERGY-AI site, Philadelphia, Pennsylvania
- Locations
- 68 in total
- Run by
- Massive Bio, Inc.
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.